|
|
|
News and Events
|
|
|
|
|
June 8, 2007 BioRelix, Inc. Announces $25.75 Million Series A Financing to Fund Development of Antibiotic Product Pipeline: NEW HAVEN, Conn.--(BUSINESS WIRE)--BioRelix, Inc., a biopharmaceutical company focused on the development of novel anti-infective agents, announced today the completion of a $25.75 million Series A financing. The financing was led by CHL Medical Partners with participation by new investors New Leaf Venture Partners and Aisling Capital and existing investors Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. BioRelix expects to use the funds to build a portfolio of anti-infective product candidates based on novel patented bacterial RNA targets, termed RiboSwitches™, which were identified by the laboratory of BioRelix’ co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University.
|
| |
|
|
November 13, 2007
NEW HAVEN, CT, and TORONTO, Nov. 13 /PRNewswire/ - biorelix, pioneers in the discovery and development of RiboSwitch based therapeutic agents and Dalton Medicinal Chemistry, have jointly announced a research collaboration to discover new therapeutics.
Dalton Medicinal Chemistry will utilize their proprietary insights to design and synthesize several novel classes of compounds against selected RiboSwitch targets. biorelix will advance these compounds using their cutting edge battery of biological assays and thorough knowledge of RiboSwitch drug discovery and development.
Brian Dixon, biorelix CEO commented: "We are pleased to have the opportunity to work with the creative team at dalton Medicinal Chemistry in the discovery of new entities for treating infectious diseases. Their expertise, coupled with our proprietary and leading position in RiboSwitch technology will lead to important new medicines."
Judd Berman, Co-founder of dalton Medicinal Chemistry, said: "We are delighted to have this opportunity to work with biorelix in the discovery of much needed new anti-infective agents. The team at biorelix has clearly established an exceptionally innovative approach to anti-infectives."
About biorelix
BioRelix Pharmaceuticals, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. biorelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed RiboSwitches, which were identified in the laboratory of biorelix co-founder, Ronald Breaker Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. biorelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.
About dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a dalton Pharma Services is a Health Canada approved contract pharmaceutical manufac
|
| |
|
|
|
|
